<DOC>
	<DOCNO>NCT00574080</DOCNO>
	<brief_summary>Add three drug , bortezomib , thalidomide , dexamethasone ( VTD ) high dose chemotherapy regimen immediately transplant ( DPACE/Melphalan ) try improve myeloma response acquire long survival participant .</brief_summary>
	<brief_title>UARK 2006-15 : A Study Tandem Transplants With Without Bortezomib Thalidomide</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients symptomatic multiple myeloma , sensitive refractory least one prior line chemotherapy . Karnofsky performance score &gt; 60 % , unless due MM . Patients must &lt; 75 year age time registration . Patient must prior auto allotransplant . Patient must sign IRBapproved informed consent understand investigational nature study . Negative serology HIV . Baseline biopsies laboratory study complete within 35 day registration , within 60 day scans radiological study ; patient must history severe chronic obstructive chronic restrictive pulmonary disease . Patients must adequate pulmonary function study &gt; 50 % predict mechanical aspect ( FEV1 , FVC , etc ) diffusion capacity ( DLCO ) &gt; 50 % predict . Patients unable complete pulmonary function test myelomarelated chest pain , must high resolution CT scan chest must also acceptable arterial blood gas define P02 great 70 . Patients recent ( &lt; 6 month ) myocardial infarction , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control cardiac arrhythmia ineligible . Ejection fraction ECHO MUGA must &gt; 40 % must perform within 60 day prior registration , unless patient receive chemotherapy within period time ( dexamethasone thalidomide exclude ) , case LVEF must repeat . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free least three year . Prior malignancy acceptable provide evidence disease within threeyear interval malignancy consider much less life threaten myeloma . Pregnant nursing woman may participate . Women childbearing potential must negative pregnancy document within one week registration . Women/men reproductive potential may participate unless agree use effective contraceptive method . Patients must able receive full dos D PACE , opinion treat investigator , exception patient creatinine clearance 3050 ml/min receive 50 % cisplatin dose . Fever active infection require intravenous antibiotic , define fever antibiotic within 72 hour baseline . Severe renal dysfunction , define creatinine &gt; 3mg/dl creatinine clearance &lt; 30ml/min . Significant neurotoxicity , define grade &gt; 3 neurotoxicity per NCI Common Toxicity Criteria ( See Appendix ) . Platelet count &lt; 100,000/mm^3 , ANC &lt; 1,000/Î¼l POEMS Syndrome . Clinically significant hepatic dysfunction note direct bilirubin AST &gt; 3 time upper normal limit clinically significant concurrent hepatitis . New York Hospital Association ( NYHA ) Class III Class IV heart failure . Myocardial infarction within last 6 month . Patients history treatment clinically significant ventricular cardiac arrhythmia . Poorlycontrolled hypertension , diabetes mellitus , serious medical illness psychiatric illness could potentially interfere completion treatment accord protocol . Prior adriamycin exposure &gt; 450 mg/m^2 Prior exposure thalidomide result severe toxicity require drug discontinuation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>